Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actos' Bladder Cancer Signal May Hinge On Dose, Duration Of Use

This article was originally published in The Pink Sheet Daily

Executive Summary

A five-year interim analysis of a 10-year epidemiological study showed no significant overall increased risk between exposure to Takeda's pioglitazone and bladder cancer, although an increased risk was seen among patients with the highest cumulative dose and the longest duration of exposure.

You may also be interested in...



Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box

In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?

Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box

In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?

First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk

TOKYO - Takeda Pharmaceutical Co. bestseller Actos has been withdrawn for new patients in France and Germany due to a long-suspected bladder cancer risk. Besides shrinking some of the excitement around the European boost Takeda received with its acquisition of Nycomed AS, the withdrawals also call into question the remaining revenue Actos can generate before its main patents expire

Related Content

Topics

UsernamePublicRestriction

Register

PS071188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel